XTL Biopharmaceuticals Ltd.
XTLBHealthcare|Biotechnology|IL
$1.55
-0.16 (-9.36%)
Cash / Share
$0.02
Financials
Financial Snapshot
Market Cap
$1.5M
Enterprise Value
$4.5M
Revenue (TTM)
$451.0K
Net Income (TTM)
-$1.0M
Cash & Investments
$144.0K
Net Cash
-$125.0K
Free Cash Flow (TTM)
$0.00
Operating CF (TTM)
$0.00
Debt/Equity
-1.06
Cash Runway & Burn Rate
Company is cash-flow positive.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $2.4M | $6.1M | $8.1M | $6.7M | $6.0M | $6.1M | $3.7M | $2.0M | $1.1M | $144.0K | $144.0K | |
| Operating Cash Flow | -$1.7M | -$1.1M | -$816.0K | -$908.0K | -$850.0K | -$1.0M | -$901.0K | -$707.0K | -$1.6M | -$1.0M | $0.00 | |
| Free Cash Flow | -$1.8M | -$1.1M | -$816.0K | -$910.0K | -$851.0K | -$1.0M | -$901.0K | -$707.0K | -$1.7M | -$1.0M | $0.00 | |
| Capital Expenditure | -$66.0K | $0.00 | $0.00 | -$2.0K | -$1.0K | $0.00 | $0.00 | $0.00 | -$54.0K | $0.00 | $0.00 | |
| Financing Cash Flow | $0.00 | $4.9M | $0.00 | $0.00 | $0.00 | $385.0K | $0.00 | $0.00 | $1.4M | $208.0K | $0.00 |
R&D Spending
R&D (TTM)
$98.0K
R&D Intensity
21.7%
R&D Growth vs Prior
+250.0%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $451.0K | $0.00 | $451.0K | |
| R&D Expense | $443.0K | $43.0K | $38.0K | $35.0K | $38.0K | $30.0K | $30.0K | $31.0K | $98.0K | $28.0K | $98.0K | |
| R&D % of Revenue | — | — | — | — | — | — | — | — | 21.7% | — | 21.7% | |
| SG&A | $1.3M | $1.2M | $755.0K | $807.0K | $910.0K | $1.0M | $850.0K | $734.0K | $2.0M | $1.1M | $2.0M |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $451.0K | $0.00 | $451.0K | |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $1.0K | $1.0K | $1.0K | $0.00 | $448.0K | $0.00 | $332.0K | |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 | -$1.0K | -$1.0K | -$1.0K | $0.00 | $3.0K | $0.00 | $119.0K | |
| R&D | $443.0K | $43.0K | $38.0K | $35.0K | $38.0K | $30.0K | $30.0K | $31.0K | $98.0K | $28.0K | $98.0K | |
| SG&A | $1.3M | $1.2M | $755.0K | $807.0K | $910.0K | $1.0M | $850.0K | $734.0K | $2.0M | $1.1M | $2.0M | |
| Operating Income | -$2.6M | -$1.2M | -$793.0K | -$842.0K | -$948.0K | -$1.0M | -$880.0K | -$765.0K | -$2.2M | -$1.7M | -$2.2M | |
| Interest Expense | $0.00 | $8.0K | $7.0K | $29.0K | $17.0K | $21.0K | $11.0K | $4.0K | $86.0K | $7.0K | $86.0K | |
| Pretax Income | -$2.5M | -$781.0K | $3.0M | -$1.3M | -$3.0M | $435.0K | -$1.3M | -$1.8M | -$1.2M | -$759.0K | -$1.2M | |
| Net Income | -$2.5M | -$781.0K | $3.0M | -$1.3M | -$782.0K | $435.0K | -$1.3M | -$1.8K | -$1.0M | -$7.0M | -$1.0M | |
| EPS (Diluted) | -14.88 | -2.72 | 9.28 | -4.16 | -9.12 | 1.12 | -4.00 | -30.00 | -2.40 | -16.00 | -2.88 | |
| EBITDA | -$1.7M | -$1.2M | -$792.0K | $0.00 | -$947.0K | -$1.0M | -$879.0K | -$764.0K | -$930.0K | -$752.0K | -$156.3K | |
| Shares Out. (M) | 0.17 | 0.29 | 0.32 | 0.32 | 0.32 | 0.38 | 0.34 | 0.34 | 0.44 | 0.44 | 0.44 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.0M | $3.3M | $3.3M | $4.5M | $3.6M | $3.0M | $2.1M | $1.4M | $371.0K | $76.0K | $76.0K | |
| Short-Term Investments | $414.0K | $2.8M | $4.9M | $2.3M | $2.4M | $3.2M | $1.6M | $605.0K | $772.0K | $68.0K | $68.0K | |
| Total Current Assets | $2.8M | $6.2M | $8.2M | $6.8M | $6.1M | $6.2M | $3.8M | $2.0M | $1.3M | $166.0K | $166.0K | |
| Total Assets | $3.0M | $6.6M | $8.6M | $7.2M | $6.5M | $6.6M | $4.2M | $2.4M | $8.6M | $166.0K | $166.0K | |
| Total Current Liabilities | $330.0K | $300.0K | $253.0K | $232.0K | $254.0K | $231.0K | $187.0K | $206.0K | $2.2M | $420.0K | $420.0K | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $330.0K | $3.0M | $253.0K | $232.0K | $254.0K | $1.3M | $187.0K | $206.0K | $3.1M | $420.0K | $420.0K | |
| Stockholders' Equity | $2.7M | $3.6M | $8.3M | $7.0M | $3.6M | $5.3M | $4.0M | $2.2M | $5.4M | -$254.0K | -$254.0K | |
| Retained Earnings | -$154.9M | -$155.6M | -$152.6M | -$153.9M | -$155.6M | -$155.1M | -$156.5M | -$158.2M | -$159.0M | -$165.6M | -$165.6M |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$1.7M | -$1.1M | -$816.0K | -$908.0K | -$850.0K | -$1.0M | -$901.0K | -$707.0K | -$1.6M | -$1.0M | $0.00 | |
| Capital Expenditure | -$66.0K | $0.00 | $0.00 | -$2.0K | -$1.0K | $0.00 | $0.00 | $0.00 | -$54.0K | $0.00 | $0.00 | |
| Free Cash Flow | -$1.8M | -$1.1M | -$816.0K | -$910.0K | -$851.0K | -$1.0M | -$901.0K | -$707.0K | -$1.7M | -$1.0M | $0.00 | |
| Investing Cash Flow | -$66.0K | -$2.5M | $778.0K | $2.1M | $32.0K | $8.0K | $36.0K | $41.0K | -$844.0K | $522.0K | $0.00 | |
| Financing Cash Flow | $0.00 | $4.9M | $0.00 | $0.00 | $0.00 | $385.0K | $0.00 | $0.00 | $1.4M | $208.0K | $0.00 | |
| Issuance of Stock | $0.00 | $4.9M | $0.00 | $0.00 | $0.00 | $385.0K | $0.00 | $0.00 | $1.5M | $0.00 | $0.00 | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$13.0K | $208.0K | $0.00 | |
| Stock Based Comp. | $182.0K | $40.0K | $24.0K | $5.0K | $51.0K | $37.0K | $14.0K | $3.0K | $264.0K | $346.0K | $264.0K | |
| Net Change in Cash | -$1.8M | $1.3M | -$34.0K | $1.2M | -$824.0K | -$662.0K | -$875.0K | -$693.0K | -$1.0M | -$295.0K | $0.00 |
Dilution Tracker
Shares outstanding grew 36.9% over 5 years — significant dilution
Shares Outstanding
9M
5-Year Share Growth
+36.9%
Stock Issuance (TTM)
$0.00
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.17 | 0.29 | 0.32 | 0.32 | 0.32 | 0.38 | 0.34 | 0.34 | 0.44 | 0.44 | 0.44 | |
| Change vs Prior % | — | 71.6% | 9.4% | 0.0% | 0.0% | 19.7% | -11.5% | -0.0% | 29.2% | 0.0% | 0.0% | |
| Stock Issuance | $0.00 | $4.9M | $0.00 | $0.00 | $0.00 | $385.0K | $0.00 | $0.00 | $1.5M | $0.00 | $0.00 | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $182.0K | $40.0K | $24.0K | $5.0K | $51.0K | $37.0K | $14.0K | $3.0K | $264.0K | $346.0K | $264.0K |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | — | — | — | — | — | — | — | — | 0.7% | — | 26.4% | |
| Operating Margin % | — | — | — | — | — | — | — | — | -481.6% | — | -481.6% | |
| Net Margin % | — | — | — | — | — | — | — | — | -227.7% | — | -227.7% | |
| EBITDA Margin % | — | — | — | — | — | — | — | — | -206.2% | — | -34.6% | |
| FCF Margin % | — | — | — | — | — | — | — | — | -370.7% | — | 0.0% | |
| ROE % | -94.7% | -21.6% | 35.9% | -19.3% | -21.7% | 8.2% | -33.7% | -0.1% | -18.9% | 2743.7% | -269.0% | |
| ROA % | -84.4% | -11.9% | 34.8% | -18.7% | -12.0% | 6.6% | -32.2% | -0.1% | -12.0% | -4198.2% | -4198.2% | |
| ROIC % | -95.3% | -19.8% | -9.5% | -11.4% | -15.2% | -16.1% | -22.0% | -34.5% | -29.7% | -11253.3% | -11253.3% | |
| R&D / Revenue % | — | — | — | — | — | — | — | — | 21.7% | — | 21.7% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -100.0% | |
| Gross Profit | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 100.0% | 0.0% | -100.0% | |
| Operating Income | 29.1% | 51.3% | 36.4% | -6.2% | -12.6% | -8.8% | 14.6% | 13.1% | -183.9% | 22.3% | |
| Net Income | 41.0% | 69.3% | 482.3% | -145.1% | 41.9% | 155.6% | -409.9% | 99.9% | -57531.9% | -578.6% | |
| EPS (Diluted) | 42.9% | 81.7% | 441.2% | -144.8% | -119.2% | 112.3% | -457.1% | -650.0% | 92.0% | -566.7% | |
| Operating Cash Flow | 6.9% | 35.0% | 27.5% | -11.3% | 6.4% | -23.4% | 14.1% | 21.5% | -128.9% | 36.7% | |
| Free Cash Flow | 6.7% | 37.4% | 27.5% | -11.5% | 6.5% | -23.3% | 14.1% | 21.5% | -136.5% | 38.7% | |
| R&D Expense | -23.4% | -90.3% | -11.6% | -7.9% | 8.6% | -21.1% | 0.0% | 3.3% | 216.1% | -71.4% | |
| SG&A Expense | -10.6% | -5.4% | -36.8% | 6.9% | 12.8% | 10.0% | -15.1% | -13.6% | 178.7% | -44.8% | |
| Total Assets | -43.3% | 118.3% | 30.2% | -15.9% | -9.8% | 1.8% | -36.7% | -42.0% | 252.4% | -98.1% | |
| Book Value / Share | -47.1% | -21.5% | 110.3% | -16.1% | -10.5% | -17.5% | -26.8% | -44.5% | 98.2% | -104.7% | |
| Debt | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 94.9% | |
| Diluted Shares | 3.9% | 71.6% | 9.4% | 0.0% | 0.0% | 19.7% | -11.5% | -0.0% | 29.2% | 0.0% |
Valuation
P/E (TTM)At Loss
P/S0.00
P/B-15.58
10Y Low / Med / High0.25 / 0.63 / 1.08
EV/EBITDAAt Loss
10Y Low / Med / High0.03 / 0.51 / 1.30
EV/Revenue0.00
P/FCFAt Loss
Intrinsic Value Models (per share)
Cash / Share
$0.02
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -0.85 | -3.37 | 0.75 | -1.32 | -1.33 | 8.66 | -1.21 | -0.13 | -3.38 | -0.14 | -0.55 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.57 | 0.00 | 0.00 | |
| P/B Ratio | 0.80 | 0.74 | 0.27 | 0.25 | 1.08 | 0.69 | 0.41 | 0.62 | 0.63 | -3.84 | -15.58 | |
| EV/EBITDA | -0.08 | 0.48 | 1.30 | 0.00 | -0.28 | -0.69 | 0.51 | 0.03 | -3.42 | -1.55 | -3.58 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.06 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
-1416.48
Distress
Piotroski F-Score
2
Weak